Massive Pulmonary Embolism

Quick Reference

Critical Alerts

Critical Alert: HEMODYNAMIC INSTABILITY DEFINES MASSIVE PE: Sustained systolic BP less than 90 mmHg, drop ≥40 mmHg for > 15 minutes, or obstructive shock requiring vasopressors. [1]

Critical Alert: THROMBOLYSIS IS FIRST-LINE FOR MASSIVE PE: Systemic thrombolysis reduces mortality by 50% compared to anticoagulation alone in hemodynamically unstable patients. [2]

Critical Alert: RIGHT VENTRICULAR DYSFUNCTION PREDICTS MORTALITY: RV failure is the primary mechanism of death in massive PE; assess with bedside echocardiography immediately. [3]

Critical Alert: DO NOT DELAY ANTICOAGULATION: Initiate unfractionated heparin immediately upon clinical suspicion, even before imaging confirmation. [1]

Critical Alert: FLUID RESUSCITATION IS DANGEROUS: Aggressive volume loading worsens RV failure through septal bowing and decreased LV preload. Limit boluses to 250-500 mL maximum. [4]

Critical Alert: PEA ARREST WITH SUSPECTED PE: Administer empiric thrombolysis (alteplase 50 mg IV bolus) during CPR and continue resuscitation for 60-90 minutes. [5]

Key Diagnostic Findings

Emergency Treatment Algorithm

Vasopressor Protocol

---

Definition and Classification

Overview

Massive pulmonary embolism (PE), now termed "high-risk PE" in contemporary guidelines, represents the most severe form of acute venous thromboembolism (VTE) characterized by hemodynamic instability resulting from acute right ventricular (RV) failure. [1] The condition demands immediate recognition and aggressive reperfusion therapy, as untreated mortality exceeds 50% within hours of presentation. [2]

The pathophysiology centers on acute obstruction of pulmonary arterial circulation by thromboembolic material, typically originating from deep venous thrombosis (DVT) of the lower extremities or pelvis. When clot burden exceeds 30-50% of pulmonary vascular cross-sectional area, or when pre-existing cardiopulmonary disease limits reserve, acute RV pressure overload precipitates rapid cardiovascular collapse. [3]

Contemporary classification from the European Society of Cardiology (ESC) and American Heart Association (AHA) stratifies acute PE by early mortality risk rather than clot burden, reflecting the prognostic importance of hemodynamic status and RV function over anatomical extent of disease. [1,16]

ESC/AHA Risk Stratification (2019)

Hemodynamic Instability Criteria (ESC 2019)

The following criteria define hemodynamic instability in acute PE: [1]

1. Cardiac arrest: Requiring cardiopulmonary resuscitation
2. Obstructive shock:
   • Systolic BP less than 90 mmHg OR vasopressors required to maintain SBP ≥90 mmHg
   • AND evidence of end-organ hypoperfusion (altered mental status, cold/clammy skin, oliguria, elevated lactate)
3. Persistent hypotension:
   • Systolic BP less than 90 mmHg OR drop ≥40 mmHg from baseline
   • Duration > 15 minutes
   • NOT caused by new-onset arrhythmia, hypovolemia, or sepsis

Exam Detail: Distinguishing Massive from Submassive PE:

The critical distinction lies in hemodynamic stability, not clot burden. A patient with a large saddle embolus but stable hemodynamics is classified as intermediate-risk (submassive), while a patient with smaller but critically positioned emboli causing hemodynamic collapse is high-risk (massive). This classification determines the threshold for reperfusion therapy:

• Massive PE: Reperfusion is indicated regardless of bleeding risk (Class I recommendation) [1]
• Submassive PE: Reperfusion considered only if clinical deterioration despite anticoagulation (Class IIa) [16]

The PEITHO trial demonstrated that routine thrombolysis in normotensive intermediate-risk PE reduced hemodynamic decompensation but increased major bleeding, including intracranial hemorrhage, without mortality benefit. [2] Therefore, systemic thrombolysis is reserved for patients who are hemodynamically unstable or deteriorating.

---

Epidemiology

Incidence and Prevalence

Pulmonary embolism represents the third leading cause of cardiovascular mortality after myocardial infarction and stroke, with an annual incidence of 100-200 cases per 100,000 population in Western countries. [17] Among hospitalized patients, VTE incidence rises to 100-300 per 100,000, making it a leading cause of preventable hospital death. [1]

Risk Factors

Risk factors for venous thromboembolism align with Virchow's triad (stasis, endothelial injury, hypercoagulability) and demonstrate cumulative effect: [1]

Clinical Pearl: High-Risk Features for Massive PE:

While any VTE risk factor can lead to massive PE, certain features predict higher clot burden and hemodynamic compromise:

1. Central venous catheter: Associated with upper extremity DVT and paradoxical embolism
2. Recent major surgery (especially orthopaedic, pelvic, neurosurgery): Large thrombus formation
3. Active malignancy: Hypercoagulable state with large, recurrent emboli
4. Prior VTE: Suggests underlying prothrombotic tendency
5. Prolonged immobility: Large iliofemoral DVT prone to embolization
6. Right heart pathology: Pre-existing RV dysfunction reduces reserve

The combination of saddle embolus and pre-existing cardiopulmonary disease carries particularly poor prognosis, as hemodynamic reserve is already compromised.

---

Pathophysiology

Mechanism of Hemodynamic Collapse

The pathophysiology of massive PE involves a cascade of hemodynamic derangements initiated by acute pulmonary vascular obstruction: [3,4]

Stage 1: Pulmonary Vascular Obstruction

1. Mechanical obstruction: Thromboembolic material physically occludes pulmonary arterial bed
2. Vasoconstriction: Hypoxemia and release of vasoactive mediators (thromboxane A2, serotonin) compound mechanical obstruction
3. Critical threshold: Hemodynamic compromise typically occurs when > 30-50% of pulmonary vascular bed is obstructed (lower threshold in patients with pre-existing cardiopulmonary disease)

Stage 2: Acute Right Ventricular Failure

1. Increased RV afterload: Pulmonary vascular resistance (PVR) rises abruptly
2. RV dilatation: Thin-walled RV cannot generate sustained pressures > 50 mmHg acutely
3. RV wall stress increases: Follows Law of Laplace (wall stress = pressure × radius / wall thickness)
4. RV ischemia: Increased wall stress compresses coronary perfusion; RV coronary flow occurs in both systole and diastole (unlike LV), making it vulnerable to systemic hypotension

Stage 3: Interventricular Dependence

1. Septal shift: RV dilatation displaces interventricular septum leftward ("D-sign" on echocardiography)
2. LV underfilling: Leftward septal shift impairs LV diastolic filling
3. Reduced cardiac output: LV stroke volume falls despite preserved LV contractility
4. Systemic hypotension: Decreased cardiac output leads to shock

Stage 4: Death Spiral

1. Coronary hypoperfusion: Systemic hypotension reduces coronary perfusion pressure
2. RV ischemia worsens: Already stressed RV becomes ischemic
3. RV contractility fails: Progressive RV dysfunction
4. PEA arrest: Final common pathway

Exam Detail: The Hemodynamic Paradox of Massive PE:

Unlike left ventricular failure where fluid resuscitation may improve preload and output, aggressive volume loading in massive PE is harmful because:

1. RV is already volume-overloaded: Additional volume worsens RV dilatation
2. Septal shift worsens: More RV distension pushes septum further left
3. LV filling decreases: Paradoxically, more volume to RV means less filling of LV
4. Tricuspid regurgitation increases: RV dilatation worsens TR, creating volume overload cycle

This is why current guidelines recommend limiting fluid boluses to 250-500 mL maximum and prioritizing vasopressor support to maintain coronary perfusion pressure. [4]

McConnell's Sign Explained:

McConnell's sign describes akinesia of the mid-free wall of the RV with preserved apical motion. The mechanism is:

1. The RV apex is tethered to the LV apex, which continues to contract
2. The mid-free wall, lacking this tethering, becomes akinetic due to acute pressure overload
3. This pattern is relatively specific for acute PE (77% specificity) and helps distinguish from chronic RV dysfunction [7]

Changes in Pulmonary Physiology

---

Clinical Presentation

Symptoms

The clinical presentation of massive PE is often dramatic but can be nonspecific. The classic triad of dyspnea, pleuritic chest pain, and hemoptysis is present in less than 20% of cases. [1]

Clinical Pearl: Syncope as a Red Flag:

Syncope as the presenting symptom of PE strongly suggests massive or near-massive PE. The PESIT study found that PE was identified in 17.3% of patients hospitalized for a first episode of syncope, with higher rates in those with traditional VTE risk factors. [19]

Mechanism of syncope in PE:

1. Transient complete pulmonary vascular obstruction → no cardiac output → LOC
2. Vasovagal response to acute RV distension
3. Arrhythmia (often transient) from RV strain

Any patient presenting with syncope should have PE considered in the differential, especially if:

• No prodrome (cardiac syncope pattern)
• Associated dyspnea before or after event
• VTE risk factors present
• Tachycardia or hypoxia in ED

Physical Examination Findings

Signs Specific to Massive PE

---

Red Flags and Life-Threatening Presentations

Immediate Life Threats

Features Suggesting Imminent Deterioration

• Persistent tachycardia despite fluid bolus
• Rising lactate
• New arrhythmia (especially atrial fibrillation)
• Declining mental status
• Worsening hypoxia despite oxygen
• Increasing vasopressor requirements
• Elevated troponin and BNP trending upward

Critical Alert: Warning Signs of Impending Arrest:

1. Bradycardia developing in a previously tachycardic patient (loss of sympathetic reserve)
2. Worsening acidosis despite resuscitation (lactate > 4 rising)
3. New complete right bundle branch block
4. Flash pulmonary edema (paradoxically due to LV underfilling then sudden RV failure)
5. Patient states "I'm going to die" (profound sense of doom)

These warrant IMMEDIATE escalation to thrombolysis or ECMO if available.

---

Differential Diagnosis

Must-Consider Alternatives

Exam Detail: The Hypotensive Dyspneic Patient: Diagnostic Approach

When facing a patient with hypotension and dyspnea, use the "SHOCK" mnemonic to systematically consider causes:

• S: Sepsis (infectious source, fever, warm shock initially)
• H: Hypovolemic (hemorrhage, GI losses, third-spacing)
• O: Obstructive (PE, tamponade, tension pneumothorax)
• C: Cardiogenic (MI, arrhythmia, valvular, cardiomyopathy)
• K: anaphylactiK (allergen, airway, skin findings)

Bedside echocardiography is the SINGLE most useful test in the undifferentiated shock patient because it can:

1. Identify RV dilatation and strain → PE
2. Show pericardial effusion → tamponade
3. Demonstrate global LV dysfunction → cardiogenic shock
4. Reveal hyperdynamic LV with collapsed IVC → septic/hypovolemic
5. Occasionally visualize thrombus-in-transit

---

Diagnostic Approach

Pre-Test Probability Assessment

In the hemodynamically unstable patient with suspected massive PE, formal probability scoring (Wells, Geneva) is LESS important because: [1]

1. Clinical suspicion is typically high
2. Delay for scoring is inappropriate
3. Management proceeds emergently regardless

However, for documentation and completeness:

Wells Score for PE:

Imaging in Massive PE

CT Pulmonary Angiography (CTPA)

CTPA is the gold standard diagnostic test but requires the patient to be stable enough for transfer to the CT scanner. [6]

Key CTPA Findings in Massive PE:

Clinical Pearl: When CTPA is Not Feasible:

In the hemodynamically unstable patient, transferring to CT scanner may be impossible or dangerous. In this situation:

1. Bedside echocardiography showing RV dilatation and dysfunction is sufficient justification for thrombolysis if clinical suspicion is high [1]
2. Lower extremity Doppler showing DVT in a patient with compatible symptoms supports empiric treatment
3. Empiric thrombolysis during cardiac arrest with high clinical suspicion for PE does not require imaging confirmation [5]

The risk of withholding thrombolysis from a dying patient far exceeds the risk of treating empirically based on clinical suspicion plus echo findings.

Bedside Echocardiography

Transthoracic echocardiography (TTE) is essential in massive PE for: [7]

1. Diagnosis support: RV dysfunction provides evidence for PE
2. Risk stratification: Degree of RV impairment predicts outcome
3. Treatment decision: Justifies thrombolysis when CTPA unavailable
4. Differential diagnosis: Excludes tamponade, severe LV dysfunction
5. Monitoring: Assess response to treatment

Echocardiographic Findings in Massive PE:

Other Imaging Modalities

Laboratory Investigations

Risk Stratification Scores

PESI Score (Pulmonary Embolism Severity Index)

The original PESI includes 11 variables: [18]

Simplified PESI (sPESI)

Exam Detail: Combining Risk Stratification:

Contemporary PE risk assessment integrates:

1. Hemodynamic status: Stable vs. unstable (defines high-risk)
2. Clinical severity score: PESI or sPESI
3. Imaging: RV dysfunction on echo or CT
4. Biomarkers: Troponin and BNP/NT-proBNP

For intermediate-risk patients (stable, elevated PESI/sPESI), further stratify:

• Intermediate-high: RV dysfunction AND elevated biomarkers → close monitoring, consider rescue reperfusion
• Intermediate-low: RV dysfunction OR elevated biomarkers (not both) → standard anticoagulation

This approach, codified in ESC 2019 guidelines, determines intensity of monitoring and threshold for escalation to reperfusion therapy. [1]

ECG Findings

ECG abnormalities in PE are common but nonspecific. Sinus tachycardia is the most frequent finding. [10]

---

Management

Principles of Treatment in Massive PE

1. Hemodynamic support: Judicious fluids, vasopressors, avoid intubation if possible
2. Anticoagulation: Immediate UFH (preferred in unstable patients)
3. Reperfusion therapy: Systemic thrombolysis first-line if no absolute contraindication
4. Respiratory support: High-flow oxygen; careful intubation if necessary
5. Advanced therapies: Catheter-directed therapy, surgical embolectomy, ECMO for refractory cases

Immediate Resuscitation

Hemodynamic Support

Fluid Management: [4]

• Caution: RV is already volume-overloaded
• Maximum bolus: 250-500 mL crystalloid
• Reassess: After each bolus for signs of worsening (elevated JVP, worsening hypoxia)
• Avoid: Large volume resuscitation

Vasopressor Selection: [15]

Clinical Pearl: Why Norepinephrine First:

Norepinephrine is preferred over pure inotropes because:

1. Maintains systemic vascular resistance (prevents LV underfilling)
2. Increases coronary perfusion pressure (critical for ischemic RV)
3. Modest β1 effect provides some inotropy
4. Less tachycardia than epinephrine

Dobutamine alone may worsen hypotension by reducing SVR while the increased contractility cannot overcome the obstructed pulmonary circulation.

Respiratory Support

Critical Alert: The Dangers of Intubation in Massive PE:

Endotracheal intubation in massive PE carries extreme risk because:

1. Induction agents cause vasodilation → precipitous drop in preload
2. Positive pressure ventilation reduces venous return and increases RV afterload
3. Loss of sympathetic tone during sedation removes compensatory tachycardia and vasoconstriction
4. Post-intubation cardiac arrest is common

If intubation is unavoidable:

• Use ketamine (maintains SVR, sympathetic tone) at 1-2 mg/kg
• Have vasopressors running before induction
• Push resuscitative dose of epinephrine ready (100 mcg IV)
• Start with low PEEP (5 cmH2O) and tidal volumes (6 mL/kg)
• Have thrombolytics immediately available
• Consider intubation AFTER thrombolysis begins if possible

Anticoagulation

Initial Anticoagulation

Anticoagulation is indicated immediately upon clinical suspicion of PE and should NOT be delayed for imaging confirmation in high-risk patients. [1]

Exam Detail: Why UFH is Preferred in Massive PE:

1. Short half-life (60-90 min): Can be rapidly discontinued if bleeding occurs or surgery needed
2. Reversible: Protamine sulfate provides complete reversal
3. Held during thrombolysis: Resume when aPTT less than 80 seconds post-lysis
4. Titratability: Infusion can be adjusted in unstable patient
5. Familiarity in ICU setting: Teams experienced with UFH protocols

LMWH may be transitioned to once patient is stable and no surgical intervention anticipated.

Systemic Thrombolysis

Systemic thrombolysis is the primary reperfusion strategy for massive PE with hemodynamic instability. [1,2,11]

Indications

Thrombolytic Regimens

Administration Protocol for Alteplase:

1. Obtain baseline coagulation studies (PT/INR, aPTT, fibrinogen)
2. Hold UFH infusion during alteplase administration
3. Administer alteplase 100 mg IV over 2 hours (or accelerated regimen if peri-arrest)
4. Monitor for bleeding, especially neurological status
5. Check aPTT 2 hours after completion
6. Resume UFH when aPTT less than 80 seconds (typically 2-4 hours post-lysis)

Contraindications to Thrombolysis

Clinical Pearl: Risk-Benefit in Massive PE:

When facing a patient in extremis from massive PE, the risk-benefit calculus shifts dramatically:

• Mortality without reperfusion: 50-65%
• Major bleeding with thrombolysis: 9-12%
• Intracranial hemorrhage: 1.5-3%

Even in patients with relative contraindications, the benefit of thrombolysis often outweighs risk when the alternative is death. Document the risk-benefit discussion clearly.

The ESC 2019 guidelines state: "In high-risk PE, absolute contraindications to thrombolysis become relative." [1]

Expected Response to Thrombolysis

Thrombolysis in Cardiac Arrest

For cardiac arrest (PEA or asystole) with suspected PE: [5]

1. Continue high-quality CPR
2. Administer alteplase 50 mg IV bolus during CPR
3. May repeat 50 mg bolus if no ROSC after 15-30 minutes
4. Continue CPR for 60-90 minutes after thrombolysis (lysis takes time to work)
5. If ROSC achieved, proceed with post-cardiac arrest care and anticoagulation

The TROICA trial and observational studies suggest improved outcomes with empiric thrombolysis in PE-related cardiac arrest. [5]

Catheter-Directed Therapy

Catheter-directed interventions offer an alternative to systemic thrombolysis, particularly when bleeding risk is high. [13]

The ULTIMA Trial: Demonstrated that ultrasound-facilitated CDT improved RV/LV ratio at 24 hours compared to anticoagulation alone in intermediate-risk PE. [20]

Indications for Catheter-Directed Therapy:

1. Massive PE with contraindication to systemic thrombolysis
2. Failed systemic thrombolysis (persistent hemodynamic instability)
3. Intermediate-high risk PE with clinical deterioration (alternative to rescue systemic lysis)
4. Institutions with Pulmonary Embolism Response Team (PERT) expertise

Surgical Embolectomy

Surgical pulmonary embolectomy involves cardiopulmonary bypass and direct removal of clot from the pulmonary arteries. [1,13]

Outcomes:

• Contemporary mortality: 6-8% in experienced centers (previously 20-30%)
• Best outcomes when performed before cardiac arrest or prolonged shock
• Requires sternotomy, cardiopulmonary bypass, pulmonary arteriotomy

Extracorporeal Membrane Oxygenation (ECMO)

Veno-arterial ECMO (VA-ECMO) provides temporary cardiopulmonary support as a bridge to recovery or definitive therapy. [14]

Indications:

1. Refractory cardiogenic shock despite vasopressors and thrombolysis
2. Cardiac arrest with ongoing CPR (E-CPR)
3. Bridge to surgical embolectomy when immediate surgery unavailable
4. Bridge to recovery when RV expected to improve

Cannulation:

• Peripheral VA-ECMO: Femoral vein → femoral artery
• Provides RV bypass and oxygenation
• Allows stabilization while awaiting definitive therapy

Considerations:

• Requires anticoagulation (typically UFH) during ECMO
• Thrombolysis can be administered on ECMO (increased bleeding risk)
• Limb ischemia risk with femoral arterial cannulation
• Time-limited (days to weeks maximum)

IVC Filter

Inferior vena cava (IVC) filters have a limited role in acute PE management: [1]

Important Considerations:

• Retrievable filters preferred (remove once anticoagulation feasible)
• Do NOT prevent death from existing pulmonary emboli
• Associated with long-term DVT risk if left in place
• Complications: Migration, caval thrombosis, filter fracture

---

Disposition

ICU Admission Criteria

ALL patients with massive PE require ICU admission. Additional criteria: [1]

• Hemodynamic instability (current or recent)
• Post-thrombolysis monitoring (minimum 24-48 hours)
• Vasopressor or inotrope requirement
• Mechanical ventilation or high-flow oxygen
• Arrhythmia requiring monitoring
• Intermediate-high risk with concern for deterioration
• Post-ECMO or post-surgical embolectomy

Monitoring Requirements in ICU

Transfer Considerations

Transfer to higher level of care if lacking:

1. Interventional cardiology/radiology for catheter-directed therapy
2. Cardiothoracic surgery for surgical embolectomy
3. ECMO capability for refractory shock
4. Pulmonary Embolism Response Team (PERT) for complex cases

---

Prognosis

Short-Term Outcomes

Long-Term Outcomes

Prognostic Factors

---

Follow-Up Care

Early Follow-Up (1-4 Weeks Post-Discharge)

1. Transition to oral anticoagulation: DOAC preferred (rivaroxaban, apixaban, edoxaban, dabigatran); warfarin if contraindicated
2. Assess bleeding complications
3. Symptom assessment: Persistent dyspnea, chest pain
4. Review diagnosis: Confirm PE diagnosis if any uncertainty
5. Risk factor assessment: Provoked vs. unprovoked

Intermediate Follow-Up (3-6 Months)

1. Duration of anticoagulation decision:

   • Provoked by major transient risk factor: 3 months minimum
   • Unprovoked or minor transient risk factor: Extended (may be indefinite)
   • Recurrent VTE: Indefinite unless high bleeding risk
   • Cancer-associated: LMWH or DOAC while cancer active

2. CTEPH screening: If persistent dyspnea, obtain echocardiography

3. Cancer screening (for unprovoked PE):

   • Age-appropriate cancer screening
   • CT abdomen/pelvis may be considered
   • Guidelines vary on extent of workup

4. Thrombophilia testing (selected cases):

   • Not routine
   • Consider if: Young age, strong family history, unusual site, recurrent, unprovoked
   • Test at least 2 weeks after stopping anticoagulation

Long-Term Follow-Up

1. Annual review if on extended anticoagulation
2. Monitor for post-PE syndrome
3. VTE prophylaxis counseling: Future surgery, immobilization, travel
4. Compression stockings: Not routinely recommended (SOX trial) but may help symptoms

---

Special Populations

Pregnancy

Massive PE is a leading cause of maternal mortality in developed countries. [1]

Cancer Patients

Elderly (> 75 Years)

Cardiac Arrest

For PEA or asystolic arrest with suspected PE: [5]

1. High-quality CPR
2. Empiric thrombolysis (alteplase 50 mg IV bolus)
3. May repeat bolus if no ROSC after 15-30 min
4. Continue CPR for 60-90 minutes post-thrombolysis
5. Consider E-CPR (ECMO) if available

---

Quality Metrics and Documentation

Key Performance Indicators

Documentation Checklist

• Hemodynamic status clearly documented (BP, HR, vasopressor use)
• Risk stratification performed (PESI/sPESI)
• RV function assessed (echo or CT findings)
• Biomarkers ordered (troponin, BNP)
• Thrombolysis indication and contraindications reviewed
• Time of anticoagulation initiation
• Time of thrombolysis administration
• Post-thrombolysis monitoring plan
• Complications documented
• Follow-up plan established

---

Common Exam Questions

Viva Questions

1. "A 65-year-old presents with sudden dyspnea, hypotension (BP 80/50), and elevated JVP. Bedside echo shows RV dilatation. What is your management?"

2. "What are the contraindications to systemic thrombolysis in massive PE, and how do you balance risk vs. benefit?"

3. "A patient with massive PE has a recent hemorrhagic stroke 2 months ago. What are your options?"

4. "What is McConnell's sign and what is its significance?"

5. "How do you manage a patient with confirmed PE who arrests in front of you?"

6. "What is the role of catheter-directed therapy vs. systemic thrombolysis?"

7. "A post-thrombolysis patient develops sudden altered mental status. What is your concern and immediate action?"

Model Answers

Viva Point: Q: Describe your approach to the hypotensive patient with suspected massive PE.

"This is a time-critical emergency requiring simultaneous assessment and treatment. My immediate priorities are:

First, high-flow oxygen and IV access with type and screen. I would assess hemodynamic status and start norepinephrine if BP remains below 90 systolic.

I would limit IV fluids to 250-500 mL maximum as excessive volume worsens RV failure.

I would immediately obtain a bedside echocardiogram. If this shows RV dilatation and dysfunction in a clinically compatible patient, this supports the diagnosis of massive PE.

If the patient is stable enough for CT, I would obtain CTPA for definitive diagnosis. If too unstable, I would proceed with empiric treatment based on echo findings.

Assuming massive PE is confirmed or highly probable, I would assess for absolute contraindications to thrombolysis. If none present, I would administer alteplase 100mg IV over 2 hours, or if the patient is peri-arrest, 50mg IV over 15 minutes.

Throughout, I would have ongoing communication with ICU, interventional radiology, and cardiothoracic surgery regarding rescue options including catheter-directed therapy, surgical embolectomy, or ECMO if thrombolysis fails or is contraindicated."

---

Key Clinical Pearls

Diagnostic Pearls

1. Shock + hypoxia + clear lungs = think massive PE - The absence of pulmonary crackles distinguishes from cardiogenic pulmonary edema
2. Syncope is a red flag - Suggests transient cardiovascular collapse from PE
3. Bedside echo is your friend - RV dilatation on focused echo can justify thrombolysis when CT is not feasible
4. S1Q3T3 is classic but insensitive - Present in only 10-20%; do not rely on ECG to diagnose PE
5. D-dimer is useless in massive PE - Don't delay treatment waiting for D-dimer in an unstable patient
6. A negative leg Doppler does not exclude PE - DVT is identified in only 25-50% of PE cases

Treatment Pearls

1. Fluids can kill in massive PE - The RV is already volume-overloaded; limit boluses to 250-500 mL
2. Norepinephrine first, then add dobutamine - Maintain coronary perfusion pressure before adding inotropy
3. Thrombolyse early - Delays increase mortality; don't wait for cardiac arrest
4. Accelerated lysis for peri-arrest - 50 mg over 15 minutes gets drug on board faster
5. Intubation is extremely dangerous - Avoid if possible; have vasopressors running before induction
6. Continue CPR 60-90 minutes post-lysis - Thrombolysis takes time to work in arrest

Disposition Pearls

1. Massive PE = ICU - No exceptions; all require close hemodynamic monitoring
2. Know your resources - Have transfer plan for ECMO/surgery before you need it
3. Watch for bleeding - Hourly neuro checks post-thrombolysis
4. Anticoagulate long-term - Most patients need at least 3-6 months; many need indefinite treatment
5. Screen for CTEPH - Persistent dyspnea at follow-up warrants echocardiography

---

References

1. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405

2. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402-1411. doi:10.1056/NEJMoa1302097

3. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353(9162):1386-1389. doi:10.1016/S0140-6736(98)07534-5

4. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033-3069. doi:10.1093/eurheartj/ehu283

5. Truhlář A, Deakin CD, Soar J, et al. European Resuscitation Council Guidelines for Resuscitation 2015: Section 4. Cardiac arrest in special circumstances. Resuscitation. 2015;95:148-201. doi:10.1016/j.resuscitation.2015.07.017

6. Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med. 2006;354(22):2317-2327. doi:10.1056/NEJMoa052367

7. McConnell MV, Solomon SD, Rayan ME, et al. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol. 1996;78(4):469-473. doi:10.1016/s0002-9149(96)00339-6

8. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116(4):427-433. doi:10.1161/CIRCULATIONAHA.106.680421

9. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med. 2008;178(4):425-430. doi:10.1164/rccm.200803-459OC

10. Geibel A, Zehender M, Kasper W, et al. Prognostic value of the ECG on admission in patients with acute major pulmonary embolism. Eur Respir J. 2005;25(5):843-848. doi:10.1183/09031936.05.00119704

11. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341(8844):507-511. doi:10.1016/0140-6736(93)90274-K

12. Sharifi M, Bay C, Skrocki L, et al. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). Am J Cardiol. 2013;111(2):273-277. doi:10.1016/j.amjcard.2012.09.027

13. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026

14. Corsi F, Lebreton G, Bréchot N, et al. Life-threatening massive pulmonary embolism rescued by venoarterial-extracorporeal membrane oxygenation. Crit Care. 2017;21(1):76. doi:10.1186/s13054-017-1655-8

15. Harjola VP, Mebazaa A, Čelutkienė J, et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail. 2016;18(3):226-241. doi:10.1002/ejhf.478

16. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788-1830. doi:10.1161/CIR.0b013e318214914f

17. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464-474. doi:10.1038/nrcardio.2015.83

18. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172(8):1041-1046. doi:10.1164/rccm.200506-862OC

19. Prandoni P, Lensing AW, Prins MH, et al. Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope. N Engl J Med. 2016;375(16):1524-1531. doi:10.1056/NEJMoa1602172

20. Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014;129(4):479-486. doi:10.1161/CIRCULATIONAHA.113.005544